ClinicalTrials.govpublic full text
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
type 2 diabetes mellitus, impaired glucose tolerance, canakinumab, pre diabetic, glucose intolerant, oral anti diabetic medication, insulin treatment, metabolic syndrome, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 897510
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.